Amoneta Diagnostics at AD/PD™ 2025: APO-Easy® Genotyping kit in the Context of New Therapies’ Launch
Amoneta Diagnostics is pleased to announce its’ team’s participation to the AD/PD™ 2025 conference, a major international ev...
On November 28th, our CEO, Dr. Stéphanie Boutillier, was honored to speak at “Meet&Match”, a networking event hosted by B...
We are excited to announce that our team will not only be attending but also presenting at the 2024 Clinical Trials on Alzheimer's...
Amoneta announces the CE-marking under the EU-IVDR of its APO-Easy® Genotyping Kit.
From June 24 to 27, 2024, Amoneta's parent company Firalis hosted at its premises in Huningue a Summer School for the CombiDiag Do...
Amoneta Diagnostics announces its participation in the forthcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases in Lisbon.
Huningue, France, December 12, 2023Together, Amoneta Diagnostics and the AD Data Initiative announce a collaboration to make data...